MetLife Investment Management’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $124K | Buy |
33,452
+4,707
| +16% | +$17.5K | ﹤0.01% | 2432 |
|
|
2025
Q1 | $92.8K | Sell |
28,745
-6,650
| -19% | -$21.5K | ﹤0.01% | 2562 |
|
|
2024
Q4 | $197K | Buy |
35,395
+6,312
| +22% | +$35.2K | ﹤0.01% | 2314 |
|
|
2024
Q3 | $314K | Hold |
29,083
| – | – | ﹤0.01% | 2042 |
|
|
2024
Q2 | $610K | Buy |
29,083
+7,983
| +38% | +$168K | ﹤0.01% | 1611 |
|
|
2024
Q1 | $672K | Hold |
21,100
| – | – | ﹤0.01% | 1524 |
|
|
2023
Q4 | $427K | Hold |
21,100
| – | – | ﹤0.01% | 1787 |
|
|
2023
Q3 | $269K | Buy |
21,100
+3,721
| +21% | +$47.4K | ﹤0.01% | 2022 |
|
|
2023
Q2 | $314K | Hold |
17,379
| – | – | ﹤0.01% | 1984 |
|
|
2023
Q1 | $299K | Hold |
17,379
| – | – | ﹤0.01% | 1962 |
|
|
2022
Q4 | $386K | Hold |
17,379
| – | – | ﹤0.01% | 1811 |
|
|
2022
Q3 | $140K | Hold |
17,379
| – | – | ﹤0.01% | 2500 |
|
|
2022
Q2 | $121K | Hold |
17,379
| – | – | ﹤0.01% | 2626 |
|
|
2022
Q1 | $263K | Buy |
17,379
+6,197
| +55% | +$93.7K | ﹤0.01% | 2178 |
|
|
2021
Q4 | $245K | Buy |
11,182
+3,203
| +40% | +$70.3K | ﹤0.01% | 1931 |
|
|
2021
Q3 | $215K | Buy |
+7,979
| New | +$215K | ﹤0.01% | 2050 |
|
|
2021
Q2 | – | Sell |
-4,083
| Closed | -$177K | – | 2451 |
|
|
2021
Q1 | $177K | Buy |
+4,083
| New | +$177K | ﹤0.01% | 2120 |
|